Josh DeClercq
Overview
Explore the profile of Josh DeClercq including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wyatt H, White S, Holloway H, DeClercq J, Zuckerman A, Choi L, et al.
J Manag Care Spec Pharm
. 2025 Feb;
31(3):253-261.
PMID: 40021460
Background: Oral oncolytic therapy for the management of chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), such as ibrutinib, acalabrutinib, and venetoclax, have vastly changed CLL treatment. Although effective,...
2.
Bowles M, Zuckerman A, DeClercq J, Choi L, Ellis M, Renfro C
J Manag Care Spec Pharm
. 2025 Feb;
31(2):147-156.
PMID: 39912811
Background: Many payers and pharmacy benefit managers (PBMs) use step therapy requirements and formulary alternatives to reduce prescription spending. The clinical utility and ultimate therapy outcomes for patients participating in...
3.
Collins S, Shotwell M, Strich J, Gibbs K, de Wit M, Files D, et al.
JAMA Netw Open
. 2024 Dec;
7(12):e2448215.
PMID: 39625722
Importance: Fostamatinib, a spleen tyrosine kinase inhibitor, has been reported to improve outcomes of COVID-19. Objective: To evaluate the efficacy and safety of fostamatinib in adults hospitalized with COVID-19 and...
4.
Danielle Bryan E, Renfro C, Anguiano R, Kumor L, DeClercq J, Choi L, et al.
J Manag Care Spec Pharm
. 2024 Jul;
30(7):710-718.
PMID: 38950163
Background: Patient-reported outcomes (PROs) are often used by clinicians to evaluate patient response to specialty medications used to treat multiple sclerosis (MS) and rheumatologic conditions. Identifying associations among PROs and...
5.
Georgieva D, Markley B, DeClercq J, Choi L, Zuckerman A
J Manag Care Spec Pharm
. 2024 Mar;
30(4):336-344.
PMID: 38555624
Background: Specialty pharmacists monitor patients taking multiple sclerosis (MS) disease-modifying therapies (DMTs) to evaluate response to therapy and intervene on adverse effects. These interventions have the potential to avoid health...
6.
Barnes J, Dial H, Owens W, DeClercq J, Choi L, Shah N, et al.
Epilepsy Res
. 2024 Jan;
200:107300.
PMID: 38241756
Objective: Evaluate adherence, discontinuation rates, and reasons for non-adherence and discontinuation of prescription CBD during the 12-months post-initiation period at an integrated care center. Methods: This was a prospective study...
7.
Bounajem G, DeClercq J, Collett G, Ayers G, Jain N
Arch Orthop Trauma Surg
. 2023 Oct;
144(12):5061-5070.
PMID: 37902892
Introduction: Several risk factors for revision TKA have previously been identified, but interactions between risk factors may occur and affect risk of revision. To our knowledge, such interactions have not...
8.
Cruchelow K, Peter M, Chakrabarti A, Gipson H, Gregory W, DeClercq J, et al.
Bone
. 2023 Oct;
177:116925.
PMID: 37797711
Introduction: The purpose of this study was to retrospectively examine predictors of fracture risk when adult patients experienced a denosumab treatment lapse or discontinuation in a real-world clinic setting. Materials...
9.
Rask J, Duran H, DeClercq J, Andreae M, Anders S, Banerjee A, et al.
Br J Anaesth
. 2023 Sep;
131(5):e157-e160.
PMID: 37741719
No abstract available.
10.
Shah N, Zuckerman A, Hosteng K, Fann J, DeClercq J, Choi L, et al.
Dig Dis Sci
. 2023 Sep;
68(12):4331-4338.
PMID: 37725192
Background: Dose escalation of self-injectable biologic therapy for inflammatory bowel diseases may be required to counteract loss of response and/or low drug levels. Payors often require completion of a prior...